MD4132C1 - Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells - Google Patents

Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells

Info

Publication number
MD4132C1
MD4132C1 MDA20100137A MD20100137A MD4132C1 MD 4132 C1 MD4132 C1 MD 4132C1 MD A20100137 A MDA20100137 A MD A20100137A MD 20100137 A MD20100137 A MD 20100137A MD 4132 C1 MD4132 C1 MD 4132C1
Authority
MD
Moldova
Prior art keywords
copper
mammary cancer
thiosemicarbazonato
manifesting
methanone
Prior art date
Application number
MDA20100137A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD4132B1 (en
Inventor
Aurelian Gulea
Tatiana Straistari
Donald Poirier
Victor Ţapcov
Original Assignee
Государственный Университет Молд0
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный Университет Молд0 filed Critical Государственный Университет Молд0
Priority to MDA20100137A priority Critical patent/MD4132C1/en
Publication of MD4132B1 publication Critical patent/MD4132B1/en
Publication of MD4132C1 publication Critical patent/MD4132C1/en

Links

Landscapes

  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to chemistry and medicine, namely to a biologically active complex combination of copper with thiosemicarbazone, which can be used in medicine as a cytostatic preparation in the prevention and treatment of mammary cancer.Summary of the invention consists in the synthesis of a new coordinative compound of copper with 2-benzoylpyridine thiosemicarbazone, di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} of formula:manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells.The technical result is to increase the range of coordinative compounds with anticancer activity, which at a concentration of 10-6 mol/L is about 4 times higher than the similar characteristics of the closest analogue from the class of copper thiosemicarbazonates.
MDA20100137A 2010-12-13 2010-12-13 Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells MD4132C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20100137A MD4132C1 (en) 2010-12-13 2010-12-13 Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20100137A MD4132C1 (en) 2010-12-13 2010-12-13 Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells

Publications (2)

Publication Number Publication Date
MD4132B1 MD4132B1 (en) 2011-10-31
MD4132C1 true MD4132C1 (en) 2012-05-31

Family

ID=45815291

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20100137A MD4132C1 (en) 2010-12-13 2010-12-13 Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells

Country Status (1)

Country Link
MD (1) MD4132C1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4326C1 (en) * 2013-10-22 2015-09-30 Институт Химии Академии Наук Молдовы N-(D8,13-Bicyclohomofarnesenoylamino)carbazole compound and process for cultivation of Nostoc linckia cyanobacterium with its use
MD4327C1 (en) * 2013-10-22 2015-09-30 Институт Химии Академии Наук Молдовы N-(D8,13-Bicyclohomofarnesenoyl)-3-amino-1,2,4-triazole compound and process for cultivation of Nostoc linckia cyanobacterium with its use
CN112028911A (en) * 2020-09-22 2020-12-04 广西师范大学 Zinc complex taking 2-benzoylpyridine thiosemicarbazone as ligand and synthetic method and application thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4520C1 (en) * 2016-12-16 2018-05-31 Государственный Университет Молд0 N-(4-butoxyphenyl)-2-(pyridin-2-ylmethylidene)hydrazinecarbothioamide as T-47D breast cancer cells growth inhibitor
CN109694391B (en) * 2018-12-20 2021-03-23 广西师范大学 Platinum complex taking 2-amino-5-chlorobenzophenone thiosemicarbazone as ligand and synthetic method and application thereof

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695911A (en) * 1951-08-14 1954-11-30 American Home Prod Preparation of copper compounds of thiosemicarbazones
US2723270A (en) * 1950-03-29 1955-11-08 Nepera Chemical Co Inc Thiosemicarbazones of pyridylaldehydes and pyridylketones
EP0135713A2 (en) * 1983-07-28 1985-04-03 The Wellcome Foundation Limited Antiviral combinations
SU1059870A1 (en) * 1981-09-04 1991-04-30 Институт Неорганической Химии Со Ан Ссср Complex compound of copper (11) with thiosepticarbazonic derivative of stable mitroxyl radical of imidazoline, displaying antitumoral activity
US5124351A (en) * 1989-02-27 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pharmaceutical compositions for the treatment of cancers susceptible to treatment with the copper complex of S-(methylthio)-DL-homocysteine or the L-enantimorph thereof
WO1993012782A1 (en) * 1991-10-31 1993-07-08 Elford Howard L Method of treating viral diseases
MD195C2 (en) * 1994-12-05 1995-11-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова The copper complexes with antistaphylococcus properties
WO1998051670A1 (en) * 1997-05-15 1998-11-19 Vion Pharmaceuticals, Inc. Process for the synthesis of ribonucleotide reductase inhibitors 3-ap and 3-amp
WO2001024803A2 (en) * 1999-10-04 2001-04-12 John Carter Pharmaceutical compositions containing copper, salicylic acid and vitamines c
MD1812C2 (en) * 2000-12-29 2002-06-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Copper complexes as bacteria and fungi inhibitors
US20030016692A1 (en) * 2000-10-26 2003-01-23 Wave7 Optics, Inc. Method and system for processing upstream packets of an optical network
MD2002G2 (en) * 2000-06-02 2003-03-31 Сайентифик Энд Прэдакшэн Ентерпрайз "Еталон", Л.Т.Д. Roller inlet box (variants)
MD2942C2 (en) * 2004-04-27 2006-06-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Di(µ-O)-bis(3,5-dibromosalicylidene thiosemicarbazonatocopper)
WO2006110119A1 (en) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Antineoplastic preparation
WO2007035927A2 (en) * 2005-09-23 2007-03-29 Wayne State University Isoflavonoid analogs and their metal conjugates as anti-cancer agents
WO2007035489A2 (en) * 2005-09-16 2007-03-29 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents
CN1948304A (en) * 2005-10-12 2007-04-18 桑迪亚医药技术（上海）有限责任公司 Heteraryl ring thiosemicarbazone kind compound and its derivative
CN101260121A (en) * 2007-03-07 2008-09-10 卡南吉医药科技（上海）有限公司 Complex compound of heteroaromatic thiosemicarbazone and transition metal, and application thereof in preparing antineoplastic medicine
AT505367A1 (en) * 2007-05-29 2008-12-15 Faustus Forschung Translationa New ruthenium and osmium-thiosemicarbazonato complex, useful as a drug and for preparing a medicament to treat and prevent cancer, preferably ovarian cancer, breast cancer, lung cancer and colon cancer
MD3655G2 (en) * 2007-09-03 2009-02-28 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of bis(2-hydroxy-8-phenyl-tricyclo/7.3.1.0.2,7/-tridecane-13-on-thiosemicarbazonato)copper
MD3771G2 (en) * 2008-04-30 2009-07-31 Государственный Университет Молд0 Inhibitors of 17β-HSD enzyme, stimulator for prostate cancer cell multiplication
MD3995B1 (en) * 2009-05-11 2009-12-31 Universitatea De Stat Din Moldova Use of di(Á-Ophenoxy)-di{[2-(4-aminobenzenesulfamido)-5-ethyl-1,3,4-thiadiazole]-3,5-dibromosalicylidenethiosemicarbazonato(-1)-copper} as inhibitor of mammary cancer T-47D cell proliferation
WO2010006438A1 (en) * 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
MD3996C2 (en) * 2009-05-25 2010-07-31 Государственный Университет Молд0 Perchlorates of 5-R-salicylidene-4-phenylthiosemicarbazonato(1-)-aquacopper(II) possessing properties of inhibitors of 17b-HSD enzyme activity (type 1)

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2723270A (en) * 1950-03-29 1955-11-08 Nepera Chemical Co Inc Thiosemicarbazones of pyridylaldehydes and pyridylketones
US2695911A (en) * 1951-08-14 1954-11-30 American Home Prod Preparation of copper compounds of thiosemicarbazones
SU1059870A1 (en) * 1981-09-04 1991-04-30 Институт Неорганической Химии Со Ан Ссср Complex compound of copper (11) with thiosepticarbazonic derivative of stable mitroxyl radical of imidazoline, displaying antitumoral activity
EP0135713A2 (en) * 1983-07-28 1985-04-03 The Wellcome Foundation Limited Antiviral combinations
US5124351A (en) * 1989-02-27 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pharmaceutical compositions for the treatment of cancers susceptible to treatment with the copper complex of S-(methylthio)-DL-homocysteine or the L-enantimorph thereof
WO1993012782A1 (en) * 1991-10-31 1993-07-08 Elford Howard L Method of treating viral diseases
MD195C2 (en) * 1994-12-05 1995-11-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова The copper complexes with antistaphylococcus properties
WO1998051670A1 (en) * 1997-05-15 1998-11-19 Vion Pharmaceuticals, Inc. Process for the synthesis of ribonucleotide reductase inhibitors 3-ap and 3-amp
WO2001024803A2 (en) * 1999-10-04 2001-04-12 John Carter Pharmaceutical compositions containing copper, salicylic acid and vitamines c
MD2002G2 (en) * 2000-06-02 2003-03-31 Сайентифик Энд Прэдакшэн Ентерпрайз "Еталон", Л.Т.Д. Roller inlet box (variants)
US20030016692A1 (en) * 2000-10-26 2003-01-23 Wave7 Optics, Inc. Method and system for processing upstream packets of an optical network
MD1812C2 (en) * 2000-12-29 2002-06-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Copper complexes as bacteria and fungi inhibitors
MD2942C2 (en) * 2004-04-27 2006-06-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Di(µ-O)-bis(3,5-dibromosalicylidene thiosemicarbazonatocopper)
WO2006110119A1 (en) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Antineoplastic preparation
WO2007035489A2 (en) * 2005-09-16 2007-03-29 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents
WO2007035927A2 (en) * 2005-09-23 2007-03-29 Wayne State University Isoflavonoid analogs and their metal conjugates as anti-cancer agents
CN1948304A (en) * 2005-10-12 2007-04-18 桑迪亚医药技术（上海）有限责任公司 Heteraryl ring thiosemicarbazone kind compound and its derivative
CN101260121A (en) * 2007-03-07 2008-09-10 卡南吉医药科技（上海）有限公司 Complex compound of heteroaromatic thiosemicarbazone and transition metal, and application thereof in preparing antineoplastic medicine
AT505367A1 (en) * 2007-05-29 2008-12-15 Faustus Forschung Translationa New ruthenium and osmium-thiosemicarbazonato complex, useful as a drug and for preparing a medicament to treat and prevent cancer, preferably ovarian cancer, breast cancer, lung cancer and colon cancer
MD3655G2 (en) * 2007-09-03 2009-02-28 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of bis(2-hydroxy-8-phenyl-tricyclo/7.3.1.0.2,7/-tridecane-13-on-thiosemicarbazonato)copper
MD3771G2 (en) * 2008-04-30 2009-07-31 Государственный Университет Молд0 Inhibitors of 17β-HSD enzyme, stimulator for prostate cancer cell multiplication
WO2010006438A1 (en) * 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
MD3995B1 (en) * 2009-05-11 2009-12-31 Universitatea De Stat Din Moldova Use of di(Á-Ophenoxy)-di{[2-(4-aminobenzenesulfamido)-5-ethyl-1,3,4-thiadiazole]-3,5-dibromosalicylidenethiosemicarbazonato(-1)-copper} as inhibitor of mammary cancer T-47D cell proliferation
MD3996C2 (en) * 2009-05-25 2010-07-31 Государственный Университет Молд0 Perchlorates of 5-R-salicylidene-4-phenylthiosemicarbazonato(1-)-aquacopper(II) possessing properties of inhibitors of 17b-HSD enzyme activity (type 1)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chumakov Iu. M., Tsapkov V. I., Jeanneau E., Bairac N. N., Bocelli G., Poirier D., Roy J., Gulea A. Crystal structures of copper(II) chloride, copper(II) bromide and copper(II) nitrate complexes with pyridin-2-carbaldehyde thiosemicarbazone. Cryst. Report. 2008, Vol.53, N 5, P. 786-792 *
Douglas X. West et al. Copper(II) complexes of 2-formyl-, 6-methyl-2-formyl- and 2-benzoylpyridine N(4)-(2-methylpyridinyl)-, N(4)-(2-ethylpyridinyl)- and N(4)-methyl(2-ethylpyridinyl)thiosemicarbazones. Transition Met. Chem., 21, 289-295 (1996); (regăsit în Internet la 2011.08.10, url: http://www.springerlink.com/content/g90np851733v87lk/) *
Giorgio Pelosi. Thiosemicarbazone Metal Complexes: from Structure to Activity. The Open Crystallography Journal, 2010, 3, pag. 16-28 *
Prostate cancer (the page was last modified on 08 August 2011), (regăsit în Internet la 2011.08.10, url: http://en.wikipedia.org/wiki/Prostate_cancer ) *
Tarlok S. Lobana et al. Mono- and di-nuclear complexes of thiosemicarbazones with copper(II): Synthesis, spectroscopy and structures. Polyhedron, Vol. 28, Issue 18, December 2009, Pages 3899-3906. doi:10.1016/j.poly.2009.08.028 <http://dx.doi.org/10.1016/j.poly.2009.08.028> (Rezumat regăsit în Internet la 2011.08.11 (abstract+graphical abstract), url: http://www.sciencedirect.com/science/article/pii/S0277538709005890 ) *
Tripathi Laxmi et al. Role of chelates in treatment of cancer. Indian Journal of Cancer, April-June 2007, vol. 44, issue 2, pag. 62-71 (regăsit în Internet la 2011.08.11, url: http://www.bioline.org.br/pdf?cn07011 ) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4326C1 (en) * 2013-10-22 2015-09-30 Институт Химии Академии Наук Молдовы N-(D8,13-Bicyclohomofarnesenoylamino)carbazole compound and process for cultivation of Nostoc linckia cyanobacterium with its use
MD4327C1 (en) * 2013-10-22 2015-09-30 Институт Химии Академии Наук Молдовы N-(D8,13-Bicyclohomofarnesenoyl)-3-amino-1,2,4-triazole compound and process for cultivation of Nostoc linckia cyanobacterium with its use
CN112028911A (en) * 2020-09-22 2020-12-04 广西师范大学 Zinc complex taking 2-benzoylpyridine thiosemicarbazone as ligand and synthetic method and application thereof

Also Published As

Publication number Publication date
MD4132B1 (en) 2011-10-31

Similar Documents

Publication Publication Date Title
EA201391626A1 (en) COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-STIMULATED CANCER TYPES
EA201490407A1 (en) CONTAINING HYDRAZIDE MODULATORS OF NUCLEAR TRANSPORT AND THEIR APPLICATION
UA110943C2 (en) N-acyl sulfonamideapoptosis promoters
WO2012061557A3 (en) Chemical compounds
PH12015501074A1 (en) Triazolopyrazine
EA201591753A1 (en) 3-PYRIMIDIN-4-ILOXAZOLIDIN-2-ONE AS MUTANT IDH INHIBITORS
EA201500394A1 (en) INHIBITORS DISTEMYLASE HYSTONES
MY160241A (en) 5-alkynyl-pyrimidines
PH12016500225A1 (en) Novel quinoline-substituted compound
EA201201159A1 (en) DETERATED PYRROPOLYMIDININE COMPOUNDS AS CDK4 / 6 INHIBITORS
MD4132C1 (en) Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells
MX2013000821A (en) New aminopyrazoloquinazolines.
EA201391644A1 (en) PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS FOR THEIR RECEPTION AND APPLICATION
MX2012013274A (en) Novel pyrimidine derivatives.
EA201290840A1 (en) ANTAGONISTS OF VANILOID RECEPTOR TRPV1 WITH BICYCLIC PART
EA201400339A1 (en) NEW IMIDAZOLAMINES AS MODULATORS OF KYNASE ACTIVITY
MX2011008899A (en) Novel ortho-aminoamides for the treatment of cancer.
MD4194B1 (en) Trinuclear coordinative compound tris{µ-¢3,5-dibromo-2-hydroxybenzylidene-4′-(pyridin-2-yl)-thiosemicarbazido(2-)]copper}hydrate, exhibiting antifungal activity against Candida albicans
MD4133B1 (en) [(2-Carbamotioylhydrazone)propionato(2-)]-(4-aminobenzenesulfonamide)copper, manifesting antimicrobial activity against bacteria of the genus Bacillus cereus
MD4127C1 (en) Use of di(m-S)-bis{chloro-[1-(pyridine-2-yl)ethanone-4-methylthiosemicarbazonato(1-)]copper} as substance with antimicrobial activity against Staphylococcus aureus
NZ603261A (en) Anticancer steroidal lactones unsaturated in position 7 (8)
UA112769C2 (en) AMINO-INDANE COMPOUNDS AND THEIR APPLICATIONS IN THE TREATMENT OF PAIN
MX2013002620A (en) Novel n-hydroxy-benzamides for the treatment of cancer.
HK1165797A1 (en) Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug
UA106884C2 (en) IMIDASOLIDINE-2,4-DION DERIVATIVES AND THEIR APPLICATIONS

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees